Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals

Biotechnology
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

$7.4B

Market Cap • 11/20/2026

2015

(11 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

10,4

P/S

7,8

P/EBITDA

55,7

P/OCF

37,1

P/FCF

37,4

P/E

97,8

BVPS

9

EPS

1,3

Market Cap

Market Cap

7,4B

EV

6,8B

EV/Revenue

7,2

EV/EBITDA

51,5

EV/EBIT

52,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-366,8M

Profitability

Gross Margin

90,2%

EBITDA Margin

14%

EBIT Margin

13,8%

Net Margin

11,6%

D&A/EBITDA

0%

R&D/Revenue

14,4%

Capex/Revenue

0,2%

Capex/D&A

86,3%

Capex/OCF

0,8%

SBC/OCF

22,6%

% PPE

1%

% Goodwill

0%

ROE

17,6%

ROIC

54,7%

Growth

CAGR Revenue 5Y

116,7%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,9

Quick Ratio

3,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium